Maintenance fees coming due
13 maintenance fees come due in the 12 months from Nov 19, 2026, the next on Dec 13, 2026. Unpaid by Jun 14, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 11,672,872 | Anti-Transferrin Receptor Antibody and Uses Thereof In force Fee due Dec 13, 2026 Lapses if unpaid Jun 14, 2027 · High confidence | Dyne Therapeutics, Inc. | In force | Dec 13, 2026 | Jun 14, 2027 | High confidence | |
| US 11,679,161 | Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy In force Fee due Dec 20, 2026 Lapses if unpaid Jun 21, 2027 · Medium confidence | Dyne Therapeutics, Inc. | In force | Dec 20, 2026 | Jun 21, 2027 | Medium confidence | |
| US 11,759,525 | Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy In force Fee due Mar 19, 2027 Lapses if unpaid Sep 20, 2027 · Medium confidence | Dyne Therapeutics, Inc. | In force | Mar 19, 2027 | Sep 20, 2027 | Medium confidence | |
| US 11,771,776 | Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies In force Fee due Apr 3, 2027 Lapses if unpaid Oct 4, 2027 · Medium confidence | Dyne Therapeutics, Inc. | In force | Apr 3, 2027 | Oct 4, 2027 | Medium confidence | |
| US 11,787,869 | Methods of Using Muscle Targeting Complexes to Deliver an Oligonucleotide to a Subject Having Facioscapulohumeral Muscular Dystrophy or a Disease Associated with Muscle Weakness In force Fee due Apr 17, 2027 Lapses if unpaid Oct 18, 2027 · Medium confidence | Dyne Therapeutics, Inc. | In force | Apr 17, 2027 | Oct 18, 2027 | Medium confidence | |
| US 11,795,233 | Muscle-Targeting Complex Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide In force Fee due Apr 24, 2027 Lapses if unpaid Oct 25, 2027 · Medium confidence | Dyne Therapeutics, Inc. | In force | Apr 24, 2027 | Oct 25, 2027 | Medium confidence | |
| US 11,795,234 | Methods of Producing Muscle-Targeting Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide In force Fee due Apr 24, 2027 Lapses if unpaid Oct 25, 2027 · Low confidence | Dyne Therapeutics, Inc. | In force | Apr 24, 2027 | Oct 25, 2027 | Low confidence | |
| US 11,833,217 | Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies In force Fee due Jun 5, 2027 Lapses if unpaid Dec 6, 2027 · Medium confidence | Dyne Therapeutics, Inc. | In force | Jun 5, 2027 | Dec 6, 2027 | Medium confidence | |
| US 11,839,660 | Anti-Transferrin Receptor Antibody and Uses Thereof In force Fee due Jun 12, 2027 Lapses if unpaid Dec 13, 2027 · High confidence | Dyne Therapeutics, Inc. | In force | Jun 12, 2027 | Dec 13, 2027 | High confidence | |
| US 11,844,843 | Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy In force Fee due Jun 19, 2027 Lapses if unpaid Dec 20, 2027 · Medium confidence | Dyne Therapeutics, Inc. | In force | Jun 19, 2027 | Dec 20, 2027 | Medium confidence | |
| 3 more maintenance fees coming due in the 12 months from Nov 19, 2026 · Pro | |||||||
10 of 13 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.